Juluca (Dolutegravir and Rilpivirine) Approved in US as First 2-Drug Regimen, Once-Daily, Single Pill - a Complete Regimen for the Maintenance Treatment of Virologically Suppressed HIV-1 Infection
November 22, 2017
November 22, 2017
LONDON, England, Nov. 22 -- GlaxoSmithKline issued the following news release:
Juluca is the first 2-drug regimen (2DR) comprising dolutegravir 50mg (ViiV Healthcare), an integrase strand transfer inhibitor and rilpivirine 25mg (Janssen Therapeutics, Division of Janssen Products LP), a non-nucleoside reverse transcriptase inhibitor.
Deborah Waterhouse, CEO ViiV Healthcare said, "The FDA approval of Juluca marks an important milestone in our commitment to deliver i . . .
Juluca is the first 2-drug regimen (2DR) comprising dolutegravir 50mg (ViiV Healthcare), an integrase strand transfer inhibitor and rilpivirine 25mg (Janssen Therapeutics, Division of Janssen Products LP), a non-nucleoside reverse transcriptase inhibitor.
Deborah Waterhouse, CEO ViiV Healthcare said, "The FDA approval of Juluca marks an important milestone in our commitment to deliver i . . .